Vernakalant Versus Ibutilide In Recent-Onset Atrial Fibrillation
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 101 participants.
Also called NCT01447862
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 101 participants
- Sponsor
- Registry
-
NCT01447862
-
- Other papers using this trial's data
- Vernakalant is superior to ibutilide for achieving sinus rhythm in patients with recent-onset atrial fibrillation: a randomized controlled trial at the emergency department
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Austria
- Registry status
- Completed
Technical summary
Registry record NCT01447862. Randomized; no masking; primary purpose treatment. Start 2011-10 (registry gives no type); primary completion 2015-05 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Vernakalant Versus Ibutilide In Recent-Onset Atrial Fibrillation
- Condition
- Atrial Fibrillation
- Intervention (Drug)
- Brinavess (Vernakalant)
- Intervention (Drug)
- Corvert (Ibutilide)
- Lead sponsor
- Medical University of Vienna
Record details
- Record id
cardio:ct-nct01447862- Content hash
0565c0281eacd8bb77aa60e0edc80e3e320f487c49dc9de18ccc57836e326ea1